T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma-Reference-Cited by-同舟云学术

T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma

Published:2022-08-11 Issue:6 Volume:387 Page:558-561
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Mailankody Sham¹,Landgren Ola¹

Affiliation:

1. From the Myeloma and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (S.M.); and the Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami (O.L.).

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMe2209692

Reference19 articles.

1. B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

2. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

3. Emerging immunotherapies in multiple myeloma

4. Teclistamab in Relapsed or Refractory Multiple Myeloma

5. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.;Haematologica;2024-01-18

2. Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell–Engaging Cancer Therapies;Blood Cancer Discovery;2024-01-17

3. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma;Cancers;2023-12-09

4. Inclusion criteria of currently enrolling T‐cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?;British Journal of Haematology;2023-03-14

5. GPRC5D as a novel immunotherapeutic target in multiple myeloma;Nature Reviews Clinical Oncology;2023-02-01